Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Immix Biopharma ( (IMMX) ) has issued an update.
On June 20, 2025, Immix Biopharma, Inc. held its Annual Meeting where stockholders representing 72.1% of the voting shares were present. During the meeting, the stockholders elected directors to serve until the next annual meeting and ratified the appointment of Crowe LLP as the independent registered public accounting firm for the year ending December 31, 2025.
The most recent analyst rating on (IMMX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Immix Biopharma stock, see the IMMX Stock Forecast page.
More about Immix Biopharma
Average Trading Volume: 210,574
Technical Sentiment Signal: Buy
Current Market Cap: $62.45M
Learn more about IMMX stock on TipRanks’ Stock Analysis page.